Pura Muñoz-Cánoves
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Pura Muñoz-Cánoves has a total of 44 co-authors. Here are the top co-authors by number of shared publications:
Antonio L. Serrano
Center for Genomic Regulation, Barcelona, Spain
4 shared publications- Eusebio Perdiguero
Department of Medicine and Life Sciences, Pompeu Fabra University, Barcelona, Spain
4 shared publications Mònica Suelves
Program on Differentiation and Cancer, Center for Genomic Regulation (CRG), Pompeu Fabra University (UPF), E-08003 Barcelona, Spain
4 shared publicationsMercè Jardí
Center for Genomic Regulation (CRG)
3 shared publications- Roser López-Alemany
Sarcoma Research Group, Molecular Oncology Laboratory, Bellvitge Biomedical Research Institute (IDIBELL), L'Hospitalet de Llobregat, Barcelona, Spain
3 shared publications Vanessa Ruiz-Bonilla
Center for Genomic Regulation, Pompeu Fabra University, Program on Differentiation and Cancer and Biomedicine Research Center on Neurodegenerative Diseases, Barcelona, Spain
3 shared publications
Latest Publications
- 15 July 2008
- Published by Taylor & Francis in Cell Cycle
- Vol. 7 (14) , 2208-2214
Efficient adult skeletal muscle regeneration in mice deficient in p38β, p38γ and p38δ MAP kinases
Adult skeletal muscle is a very stable tissue containing a small population of myofiber-associated quiescent satellite cells compared with late embryonic/neonatal skeletal muscle, which contains highly proliferating myoblasts and small actively growing myofibers, suggesting that specific regulatory pathways may control myogenesis at distinct developmental stages. The p38 MAPK signaling pathway is central for myogenesis, based on studies using immortalized and neonatal primary myoblasts in vitro. However, the contribution of this pathway to adult myogenesis has never been investigated. Four p38 isoforms (p38α, p38β, p38γ and p38δ) exist in mammalian cells, being p38α and p38γ the most abundantly expressed isoforms in adult skeletal muscle. Given the embryonic/neonatal lethality of p38α-deficient mice, here we investigate the relative contribution of p38β, p38γ and p38δ to adult myogenesis. Regeneration and myofiber growth of adult muscle proceeds with similar efficiency in mice lacking p38β, p38γ and p38δ as in wild-type control mice. In agreement with this, there is no difference in adult satellite cell behavior in vitro among the different genotypes. Importantly, the pattern of p38 activation (ascribed to p38α) remains unperturbed during satellite myogenesis in vitro and adult muscle regeneration in wild type and p38β-, p38γ- and p38δ-deficient mice, rendering p38α as the essential p38 isoform sustaining adult myogenesis. This study constitutes the first analysis addressing the functionality of p38β, p38γ and p38δ in satellite cell-dependent adult muscle regeneration and growth.
- 15 July 2008
- Published by Taylor & Francis in Cell Cycle
- Vol. 7 (14) , 2208-2214
Efficient adult skeletal muscle regeneration in mice deficient in p38β, p38γ and p38δ MAP kinases
Adult skeletal muscle is a very stable tissue containing a small population of myofiber-associated quiescent satellite cells compared with late embryonic/neonatal skeletal muscle, which contains highly proliferating myoblasts and small actively growing myofibers, suggesting that specific regulatory pathways may control myogenesis at distinct developmental stages. The p38 MAPK signaling pathway is central for myogenesis, based on studies using immortalized and neonatal primary myoblasts in vitro. However, the contribution of this pathway to adult myogenesis has never been investigated. Four p38 isoforms (p38α, p38β, p38γ and p38δ) exist in mammalian cells, being p38α and p38γ the most abundantly expressed isoforms in adult skeletal muscle. Given the embryonic/neonatal lethality of p38α-deficient mice, here we investigate the relative contribution of p38β, p38γ and p38δ to adult myogenesis. Regeneration and myofiber growth of adult muscle proceeds with similar efficiency in mice lacking p38β, p38γ and p38δ as in wild-type control mice. In agreement with this, there is no difference in adult satellite cell behavior in vitro among the different genotypes. Importantly, the pattern of p38 activation (ascribed to p38α) remains unperturbed during satellite myogenesis in vitro and adult muscle regeneration in wild type and p38β-, p38γ- and p38δ-deficient mice, rendering p38α as the essential p38 isoform sustaining adult myogenesis. This study constitutes the first analysis addressing the functionality of p38β, p38γ and p38δ in satellite cell-dependent adult muscle regeneration and growth.
- 1 July 2008
- Published by Cold Spring Harbor Laboratory in Genes & Development
- Vol. 22 (13) , 1747-1752
Fibrinogen drives dystrophic muscle fibrosis via a TGFβ/alternative macrophage activation pathway
In the fatal degenerative Duchenne muscular dystrophy (DMD), skeletal muscle is progressively replaced by fibrotic tissue. Here, we show that fibrinogen accumulates in dystrophic muscles of DMD patients andmdxmice. Genetic loss or pharmacological depletion of fibrinogen in these mice reduced fibrosis and dystrophy progression. Our results demonstrate that fibrinogen–Mac-1 receptor binding, through induction of IL-1β, drives the synthesis of transforming growth factor-β (TGFβ) bymdxmacrophages, which in turn induces collagen production inmdxfibroblasts. Fibrinogen-produced TGFβ further amplifies collagen accumulation through activation of profibrotic alternatively activated macrophages. Fibrinogen, by engaging its αvβ3 receptor on fibroblasts, also directly promotes collagen synthesis. These data unveil a profibrotic role of fibrinogen deposition in muscle dystrophy.
- 1 July 2008
- Published by Cold Spring Harbor Laboratory in Genes & Development
- Vol. 22 (13) , 1747-1752
Fibrinogen drives dystrophic muscle fibrosis via a TGFβ/alternative macrophage activation pathway
In the fatal degenerative Duchenne muscular dystrophy (DMD), skeletal muscle is progressively replaced by fibrotic tissue. Here, we show that fibrinogen accumulates in dystrophic muscles of DMD patients andmdxmice. Genetic loss or pharmacological depletion of fibrinogen in these mice reduced fibrosis and dystrophy progression. Our results demonstrate that fibrinogen–Mac-1 receptor binding, through induction of IL-1β, drives the synthesis of transforming growth factor-β (TGFβ) bymdxmacrophages, which in turn induces collagen production inmdxfibroblasts. Fibrinogen-produced TGFβ further amplifies collagen accumulation through activation of profibrotic alternatively activated macrophages. Fibrinogen, by engaging its αvβ3 receptor on fibroblasts, also directly promotes collagen synthesis. These data unveil a profibrotic role of fibrinogen deposition in muscle dystrophy.
- Open Access
- 4 September 2007
- Published by Rockefeller University Press in Journal of Cell Biology
- Vol. 178 (6) , 1039-1051
uPA deficiency exacerbates muscular dystrophy in MDX mice
Duchenne muscular dystrophy (DMD) is a fatal and incurable muscle degenerative disorder. We identify a function of the protease urokinase plasminogen activator (uPA) in mdx mice, a mouse model of DMD. The expression of uPA is induced in mdx dystrophic muscle, and the genetic loss of uPA in mdx mice exacerbated muscle dystrophy and reduced muscular function. Bone marrow (BM) transplantation experiments revealed a critical function for BM-derived uPA in mdx muscle repair via three mechanisms: (1) by promoting the infiltration of BM-derived inflammatory cells; (2) by preventing the excessive deposition of fibrin; and (3) by promoting myoblast migration. Interestingly, genetic loss of the uPA receptor in mdx mice did not exacerbate muscular dystrophy in mdx mice, suggesting that uPA exerts its effects independently of its receptor. These findings underscore the importance of uPA in muscular dystrophy.
- 4 September 2007
- Published by Rockefeller University Press in Journal of Cell Biology
- Vol. 178 (6) , 1039-1051
Open AccessuPA deficiency exacerbates muscular dystrophy in MDX mice
Duchenne muscular dystrophy (DMD) is a fatal and incurable muscle degenerative disorder. We identify a function of the protease urokinase plasminogen activator (uPA) in mdx mice, a mouse model of DMD. The expression of uPA is induced in mdx dystrophic muscle, and the genetic loss of uPA in mdx mice exacerbated muscle dystrophy and reduced muscular function. Bone marrow (BM) transplantation experiments revealed a critical function for BM-derived uPA in mdx muscle repair via three mechanisms: (1) by promoting the infiltration of BM-derived inflammatory cells; (2) by preventing the excessive deposition of fibrin; and (3) by promoting myoblast migration. Interestingly, genetic loss of the uPA receptor in mdx mice did not exacerbate muscular dystrophy in mdx mice, suggesting that uPA exerts its effects independently of its receptor. These findings underscore the importance of uPA in muscular dystrophy.
- 8 August 2007
- Published by Springer Nature
- p. 51-79
Transcriptional regulation by the p38 MAPK signaling pathway in mammalian cells
- 8 August 2007
- Published by Springer Nature
- p. 51-79
Transcriptional regulation by the p38 MAPK signaling pathway in mammalian cells
- 1 June 2007
- Published by Taylor & Francis in Cell Cycle
- Vol. 6 (11) , 1298-1303
Genetic Deficiency of p38α Reveals its Critical Role in Myoblast Cell Cycle Exit:The p38α-JNK Connection
The regulation of skeletal muscle formation (myogenesis) is essential for normal development as well as in pathological conditions such as muscular dystrophies and inflammatory myopathies. Findings published over the past years have established a key role for the p38 MAP kinase signaling pathway in the control of muscle gene expression and myotube formation. However, the relative contribution of the four p38 MAP kinases (p38α, p38β, p38γ and p38δ) to this process was unknown. We have recently demonstrated that myoblasts lacking p38α, but not those lacking p38β or p38δ, were unable to differentiate and form multinucleated myotubes, while p38γ-deficient myoblasts exhibited an attenuated fusion capacity. Defective myogenesis in the absence of p38α was attributed to delayed cell cycle exit and continuous proliferation in differentiation-promoting conditions, caused by enhanced activation of the JNK/cJun pathway. We discuss these findings in the context of the emerging crosstalk of p38 and JNK signaling pathways in controlling cell growth and differentiation.
- 1 June 2007
- Published by Taylor & Francis in Cell Cycle
- Vol. 6 (11) , 1298-1303
Genetic Deficiency of p38α Reveals its Critical Role in Myoblast Cell Cycle Exit:The p38α-JNK Connection
The regulation of skeletal muscle formation (myogenesis) is essential for normal development as well as in pathological conditions such as muscular dystrophies and inflammatory myopathies. Findings published over the past years have established a key role for the p38 MAP kinase signaling pathway in the control of muscle gene expression and myotube formation. However, the relative contribution of the four p38 MAP kinases (p38α, p38β, p38γ and p38δ) to this process was unknown. We have recently demonstrated that myoblasts lacking p38α, but not those lacking p38β or p38δ, were unable to differentiate and form multinucleated myotubes, while p38γ-deficient myoblasts exhibited an attenuated fusion capacity. Defective myogenesis in the absence of p38α was attributed to delayed cell cycle exit and continuous proliferation in differentiation-promoting conditions, caused by enhanced activation of the JNK/cJun pathway. We discuss these findings in the context of the emerging crosstalk of p38 and JNK signaling pathways in controlling cell growth and differentiation.
- Open Access
- 15 February 2007
- Published by Springer Nature in The EMBO Journal
- Vol. 26 (5) , 1245-1256
Genetic analysis of p38 MAP kinases in myogenesis: fundamental role of p38α in abrogating myoblast proliferation
The p38 mitogen‐activated protein kinase (MAPK) pathway plays a critical role in skeletal muscle differentiation. However, the relative contribution of the four p38 MAPKs (p38α, p38β, p38γ and p38δ) to this process is unknown. Here we show that myoblasts lacking p38α, but not those lacking p38β or p38δ, are unable to differentiate and form multinucleated myotubes, whereas p38γ‐deficient myoblasts exhibit an attenuated fusion capacity. The defective myogenesis in the absence of p38α is caused by delayed cell‐cycle exit and continuous proliferation in differentiation‐promoting conditions. Indeed, activation of JNK/cJun was enhanced in p38α‐deficient myoblasts leading to increased cyclin D1 transcription, whereas inhibition of JNK activity rescued the proliferation phenotype. Thus, p38α controls myogenesis by antagonizing the activation of the JNK proliferation‐promoting pathway, before its direct effect on muscle differentiation‐specific gene transcription. More importantly, in agreement with the defective myogenesis of cultured p38αΔ/Δ myoblasts, neonatal muscle deficient in p38α shows cellular hyperproliferation and delayed maturation. This study provides novel evidence of a fundamental role of p38α in muscle formation in vitro and in vivo .
- 15 February 2007
- Published by Springer Nature in The EMBO Journal
- Vol. 26 (5) , 1245-1256
Open AccessGenetic analysis of p38 MAP kinases in myogenesis: fundamental role of p38α in abrogating myoblast proliferation
The p38 mitogen‐activated protein kinase (MAPK) pathway plays a critical role in skeletal muscle differentiation. However, the relative contribution of the four p38 MAPKs (p38α, p38β, p38γ and p38δ) to this process is unknown. Here we show that myoblasts lacking p38α, but not those lacking p38β or p38δ, are unable to differentiate and form multinucleated myotubes, whereas p38γ‐deficient myoblasts exhibit an attenuated fusion capacity. The defective myogenesis in the absence of p38α is caused by delayed cell‐cycle exit and continuous proliferation in differentiation‐promoting conditions. Indeed, activation of JNK/cJun was enhanced in p38α‐deficient myoblasts leading to increased cyclin D1 transcription, whereas inhibition of JNK activity rescued the proliferation phenotype. Thus, p38α controls myogenesis by antagonizing the activation of the JNK proliferation‐promoting pathway, before its direct effect on muscle differentiation‐specific gene transcription. More importantly, in agreement with the defective myogenesis of cultured p38αΔ/Δ myoblasts, neonatal muscle deficient in p38α shows cellular hyperproliferation and delayed maturation. This study provides novel evidence of a fundamental role of p38α in muscle formation in vitro and in vivo .
- Open Access
- 17 February 2005
- Published by Springer Nature in The EMBO Journal
- Vol. 24 (5) , 974-984
E47 phosphorylation by p38 MAPK promotes MyoD/E47 association and muscle‐specific gene transcription
EMBO Press is an editorially independent publishing platform for the development of EMBO scientific publications.
- 17 February 2005
- Published by Springer Nature in The EMBO Journal
- Vol. 24 (5) , 974-984
Open AccessE47 phosphorylation by p38 MAPK promotes MyoD/E47 association and muscle‐specific gene transcription
EMBO Press is an editorially independent publishing platform for the development of EMBO scientific publications.
- Open Access
- 1 April 2004
- Published by American Society for Cell Biology (ASCB) in Molecular Biology of the Cell
- Vol. 15 (4) , 2013-2026
p38 MAPK-induced Nuclear Factor-κB Activity Is Required for Skeletal Muscle Differentiation: Role of Interleukin-6
P38 MAPK and nuclear factor-κB (NF-κB) signaling pathways have been implicated in the control of skeletal myogenesis. However, although p38 is recognized as a potent activator of myoblast differentiation, the role of NF-κB remains controversial. Here, we show that p38 is activated only in differentiating myocytes, whereas NF-κB activity is present both in proliferation and differentiation stages. NF-κB activation was found to be dependent on p38 activity during differentiation, being NF-κB an effector of p38, thus providing a novel mechanism for the promyogenic effect of p38. Activation of p38 in C2C12 cells induced the activity of NF-κB, in a dual way: first, by reducing IκBα levels and inducing NF-κB-DNA binding activity and, second, by potentiating the transactivating activity of p65-NF-κB. Finally, we show that interleukin (IL)-6 expression is induced in C2C12 differentiating myoblasts, in a p38- and NF-κB-dependent manner. Interference of IL-6 mRNA reduced, whereas its overexpression increased, the extent of myogenic differentiation; moreover, addition of IL-6 was able to rescue significantly the negative effect of NF-κB inhibition on this process. This study provides the first evidence of a crosstalk between p38 MAPK and NF-κB signaling pathways during myogenesis, with IL-6 being one of the effectors of this promyogenic mechanism.
- 1 April 2004
- Published by American Society for Cell Biology (ASCB) in Molecular Biology of the Cell
- Vol. 15 (4) , 2013-2026
Open Accessp38 MAPK-induced Nuclear Factor-κB Activity Is Required for Skeletal Muscle Differentiation: Role of Interleukin-6
P38 MAPK and nuclear factor-κB (NF-κB) signaling pathways have been implicated in the control of skeletal myogenesis. However, although p38 is recognized as a potent activator of myoblast differentiation, the role of NF-κB remains controversial. Here, we show that p38 is activated only in differentiating myocytes, whereas NF-κB activity is present both in proliferation and differentiation stages. NF-κB activation was found to be dependent on p38 activity during differentiation, being NF-κB an effector of p38, thus providing a novel mechanism for the promyogenic effect of p38. Activation of p38 in C2C12 cells induced the activity of NF-κB, in a dual way: first, by reducing IκBα levels and inducing NF-κB-DNA binding activity and, second, by potentiating the transactivating activity of p65-NF-κB. Finally, we show that interleukin (IL)-6 expression is induced in C2C12 differentiating myoblasts, in a p38- and NF-κB-dependent manner. Interference of IL-6 mRNA reduced, whereas its overexpression increased, the extent of myogenic differentiation; moreover, addition of IL-6 was able to rescue significantly the negative effect of NF-κB inhibition on this process. This study provides the first evidence of a crosstalk between p38 MAPK and NF-κB signaling pathways during myogenesis, with IL-6 being one of the effectors of this promyogenic mechanism.
- Open Access
- 22 January 2004
- Published by Springer Nature in The EMBO Journal
- Vol. 23 (2) , 365-375
Phosphorylation of MRF4 transactivation domain by p38 mediates repression of specific myogenic genes
Skeletal myogenesis is associated with the activation of four muscle regulatory factors (MRFs): Myf5, MyoD, Myogenin and MRF4. Here we report that p38 mitogen‐activated protein kinase represses the transcriptional activity of MRF4 (involved in late stages of myogenesis), resulting in downregulation of specific muscle genes. MRF4 is phosphorylated in vitro and in vivo by p38 on two serines (Ser31 and Ser42) located in the N‐terminal transactivation domain, resulting in reduced MRF4‐mediated transcriptional activity. In contrast, nonphosphorylatable MRF4 mutants display increased transcriptional activity and are able to advance both myoblast fusion and differentiation. We also show that expression of desmin and α‐actin, but not muscle creatin kinase, decreased at late stages of muscle differentiation, correlating with the induction of MRF4 and p38 activation. Accordingly, inhibition of p38 during late myogenesis results in the upregulation of both desmin and α‐actin. We propose that repression of MRF4 activity by p38 phosphorylation may represent a new mechanism for the silencing of specific muscle genes at the terminal stages of muscle differentiation.
- 22 January 2004
- Published by Springer Nature in The EMBO Journal
- Vol. 23 (2) , 365-375
Open AccessPhosphorylation of MRF4 transactivation domain by p38 mediates repression of specific myogenic genes
Skeletal myogenesis is associated with the activation of four muscle regulatory factors (MRFs): Myf5, MyoD, Myogenin and MRF4. Here we report that p38 mitogen‐activated protein kinase represses the transcriptional activity of MRF4 (involved in late stages of myogenesis), resulting in downregulation of specific muscle genes. MRF4 is phosphorylated in vitro and in vivo by p38 on two serines (Ser31 and Ser42) located in the N‐terminal transactivation domain, resulting in reduced MRF4‐mediated transcriptional activity. In contrast, nonphosphorylatable MRF4 mutants display increased transcriptional activity and are able to advance both myoblast fusion and differentiation. We also show that expression of desmin and α‐actin, but not muscle creatin kinase, decreased at late stages of muscle differentiation, correlating with the induction of MRF4 and p38 activation. Accordingly, inhibition of p38 during late myogenesis results in the upregulation of both desmin and α‐actin. We propose that repression of MRF4 activity by p38 phosphorylation may represent a new mechanism for the silencing of specific muscle genes at the terminal stages of muscle differentiation.
- Open Access
- 1 March 2003
- Published by Wiley in European Journal of Biochemistry
- Vol. 270 (5) , 814-821
Plasminogen activator inhibitor type‐1 inhibits insulin signaling by competing with αvβ3 integrin for vitronectin binding
Functional cooperation between integrins and growth factor receptors has been reported for several systems, one of which is the modulation of insulin signaling by αvβ3 integrin. Plasminogen activator inhibitor type‐1 (PAI‐1), competes with αvβ3 integrin for vitronectin (VN) binding. Here we report that PAI‐1, in a VN‐dependent manner, prevents the cooperation of αvβ3 integrin with insulin signaling in NIH3T3 fibroblasts, resulting in a decrease in insulin‐induced protein kinase B (PKB) phosphorylation, vascular endothelial growth factor (VEGF) expression and cell migration. Insulin‐induced HUVEC migration and angiotube formation was also enhanced in the presence of VN and this enhancement is inhibited by PAI‐1. By using specific PAI‐1 mutants with either VN binding or plasminogen activator (PA) inhibiting activities ablated, we have shown that the PAI‐1‐mediated interference with insulin signaling occurs through its direct interaction with VN, and not through its PA neutralizing activity. Moreover, using cells deficient for uPA receptor (uPAR) we have demonstrated that the inhibition of PAI‐1 on insulin signaling is independent of uPAR‐VN binding. These results constitute the first demonstration of the interaction of PAI‐1 with the insulin response.
- 1 March 2003
- Published by Wiley in European Journal of Biochemistry
- Vol. 270 (5) , 814-821
Open AccessPlasminogen activator inhibitor type‐1 inhibits insulin signaling by competing with αvβ3 integrin for vitronectin binding
Functional cooperation between integrins and growth factor receptors has been reported for several systems, one of which is the modulation of insulin signaling by αvβ3 integrin. Plasminogen activator inhibitor type‐1 (PAI‐1), competes with αvβ3 integrin for vitronectin (VN) binding. Here we report that PAI‐1, in a VN‐dependent manner, prevents the cooperation of αvβ3 integrin with insulin signaling in NIH3T3 fibroblasts, resulting in a decrease in insulin‐induced protein kinase B (PKB) phosphorylation, vascular endothelial growth factor (VEGF) expression and cell migration. Insulin‐induced HUVEC migration and angiotube formation was also enhanced in the presence of VN and this enhancement is inhibited by PAI‐1. By using specific PAI‐1 mutants with either VN binding or plasminogen activator (PA) inhibiting activities ablated, we have shown that the PAI‐1‐mediated interference with insulin signaling occurs through its direct interaction with VN, and not through its PA neutralizing activity. Moreover, using cells deficient for uPA receptor (uPAR) we have demonstrated that the inhibition of PAI‐1 on insulin signaling is independent of uPAR‐VN binding. These results constitute the first demonstration of the interaction of PAI‐1 with the insulin response.